- Home
- AAL vs ROIV Comparison
AAL vs ROIV Comparison
Compare AAL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAL | ROIV |
|---|---|---|
| Founded | 1930 | 2014 |
| Country | United States | United Kingdom |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 20.7B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AAL | ROIV |
|---|---|---|
| Price | $10.84 | $28.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $15.84 | ★ $27.56 |
| AVG Volume (30 Days) | ★ 69.0M | 4.5M |
| Earning Date | 04-23-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $54,633,000,000.00 | $29,053,000.00 |
| Revenue This Year | $11.42 | N/A |
| Revenue Next Year | $4.96 | $594.84 |
| P/E Ratio | $63.68 | ★ N/A |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $8.92 | $8.73 |
| 52 Week High | $16.50 | $30.33 |
Technical Indicators
Market Signals| Indicator | AAL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 56.22 |
| Support Level | $10.28 | $26.94 |
| Resistance Level | $11.34 | $30.33 |
| Average True Range (ATR) | 0.42 | 0.95 |
| MACD | 0.15 | -0.12 |
| Stochastic Oscillator | 60.24 | 79.20 |
Price Performance
Historical ComparisonAbout AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.